Symbols / TRAX Stock $16.17 -2.97% First Tracks Biotherapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
TRAX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Daniel R. Faga
Exch · Country NMS · United States
Market Cap 564.04M
Enterprise Value 277.58M
Income -169.38M
Sales —
FCF (ttm) —
Book/sh 7.38
Cash/sh 8.21
Employees 104
Insider 10d —
IPO Apr 06, 2026
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.04
PEG —
P/S —
P/B 2.19
P/C —
EV/EBITDA -1.54
EV/Sales —
Quick Ratio 8.65
Current Ratio 8.74
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -4.71
EPS next Y -3.21
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) —
Earnings (prior) —
ROA —
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 34.89M
Shs Float 31.08M
Insider Own 6.51%
Instit Own 39.06%
Short Float —
Short Ratio 12.58
Short Interest 4.03M
52W High 26.80
vs 52W High -39.68%
52W Low 14.79
vs 52W Low 9.30%
Beta —
Impl. Vol. 12.50%
Rel Volume 1.26
Avg Volume 387.20K
Volume 488.99K
Target (mean) $39.43
Tgt Median $40.00
Tgt Low $30.00
Tgt High $54.00
# Analysts 7
Recom Strong_buy
Prev Close $16.66
Price $16.16
Change -2.97%
About

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$39.43
Mean price target
2. Current target
$16.17
Latest analyst target
3. DCF / Fair value
$39.43
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$16.17
Low
$30.00
High
$54.00
Mean
$39.43
News
RSS: Latest TRAX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-20 ECOR1 CAPITAL, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 4,705,575 $18.60 $87,523,695
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31
Total Revenue
0.00
0.00
Operating Revenue
0.00
0.00
Operating Expense
181.10
+52.88%
118.46
Research And Development
152.34
+56.10%
97.59
Selling General And Administration
28.76
+37.81%
20.87
General And Administrative Expense
28.76
+37.81%
20.87
Other Gand A
28.76
+37.81%
20.87
Total Expenses
181.10
+52.88%
118.46
Operating Income
-181.10
-52.88%
-118.46
Total Operating Income As Reported
-181.10
-52.88%
-118.46
EBITDA
-178.70
-53.94%
-116.08
Normalized EBITDA
-178.70
-53.94%
-116.08
Reconciled Depreciation
2.40
+0.88%
2.38
EBIT
-181.10
-52.88%
-118.46
Net Income
-163.71
-54.22%
-106.15
Pretax Income
-163.71
-54.22%
-106.15
Net Non Operating Interest Income Expense
17.38
+41.17%
12.31
Net Interest Income
17.38
+41.17%
12.31
Interest Income Non Operating
17.38
+41.17%
12.31
Interest Income
17.38
+41.17%
12.31
Other Income Expense
0.01
+800.00%
-0.00
Other Non Operating Income Expenses
0.01
+800.00%
-0.00
Tax Rate For Calcs
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
Net Income Including Noncontrolling Interests
-163.71
-54.22%
-106.15
Net Income From Continuing Operation Net Minority Interest
-163.71
-54.22%
-106.15
Net Income From Continuing And Discontinued Operation
-163.71
-54.22%
-106.15
Net Income Continuous Operations
-163.71
-54.22%
-106.15
Normalized Income
-163.71
-54.22%
-106.15
Net Income Common Stockholders
-163.71
-54.22%
-106.15
Diluted EPS
—
-3.05
Basic EPS
—
-3.05
Basic Average Shares
—
34.75
Diluted Average Shares
—
34.75
Diluted NI Availto Com Stockholders
-163.71
-54.22%
-106.15
Line Item Trend 2024-12-31 2023-12-31
Total Assets
441.89
-0.50%
444.11
Current Assets
389.93
-2.16%
398.56
Cash Cash Equivalents And Short Term Investments
385.37
-1.41%
390.90
Cash And Cash Equivalents
123.08
+242.22%
35.97
Other Short Term Investments
262.29
-26.10%
354.94
Prepaid Assets
4.56
-40.40%
7.65
Other Current Assets
4.56
-40.40%
7.65
Total Non Current Assets
51.96
+14.06%
45.55
Net PPE
16.23
-11.16%
18.27
Gross PPE
22.83
-6.77%
24.49
Accumulated Depreciation
-6.60
-6.13%
-6.22
Properties
0.00
0.00
Machinery Furniture Equipment
1.53
-6.71%
1.64
Other Properties
21.10
-6.84%
22.65
Leases
0.20
+0.00%
0.20
Investments And Advances
35.47
+31.24%
27.03
Other Non Current Assets
0.26
+0.00%
0.26
Total Liabilities Net Minority Interest
50.30
+46.80%
34.26
Current Liabilities
36.18
+98.56%
18.22
Payables And Accrued Expenses
26.84
+126.43%
11.85
Payables
3.79
+56.08%
2.42
Accounts Payable
3.79
+56.08%
2.42
Current Accrued Expenses
23.05
+144.53%
9.43
Pensionand Other Post Retirement Benefit Plans Current
7.42
+61.53%
4.59
Current Debt And Capital Lease Obligation
1.93
+8.33%
1.78
Current Capital Lease Obligation
1.93
+8.33%
1.78
Total Non Current Liabilities Net Minority Interest
14.11
-12.00%
16.04
Long Term Debt And Capital Lease Obligation
14.11
-12.00%
16.04
Long Term Capital Lease Obligation
14.11
-12.00%
16.04
Stockholders Equity
391.60
-4.45%
409.85
Common Stock Equity
391.60
-4.45%
409.85
Capital Stock
391.29
-4.71%
410.65
Common Stock
391.29
-4.71%
410.65
Share Issued
34.75
+0.00%
34.75
Ordinary Shares Number
34.75
+0.00%
34.75
Gains Losses Not Affecting Retained Earnings
0.30
+138.27%
-0.80
Total Equity Gross Minority Interest
391.60
-4.45%
409.85
Total Capitalization
391.60
-4.45%
409.85
Working Capital
353.75
-6.99%
380.33
Invested Capital
391.60
-4.45%
409.85
Total Debt
16.04
-9.98%
17.81
Capital Lease Obligations
16.04
-9.98%
17.81
Net Tangible Assets
391.60
-4.45%
409.85
Tangible Book Value
391.60
-4.45%
409.85
Other Equity Interest
391.29
-4.71%
410.65
Line Item Trend 2024-12-31 2023-12-31
Operating Cash Flow
-125.81
-35.27%
-93.00
Cash Flow From Continuing Operating Activities
-125.81
-35.27%
-93.00
Net Income From Continuing Operations
-163.71
-54.22%
-106.15
Depreciation Amortization Depletion
2.40
+0.88%
2.38
Depreciation
2.40
+0.88%
2.38
Depreciation And Amortization
2.40
+0.88%
2.38
Stock Based Compensation
26.83
+45.85%
18.39
Change In Working Capital
18.99
+555.21%
2.90
Change In Prepaid Assets
2.95
+176.54%
-3.86
Change In Payables And Accrued Expense
17.81
+112.29%
8.39
Change In Payable
17.81
+112.29%
8.39
Change In Account Payable
17.81
+112.29%
8.39
Change In Other Current Liabilities
-1.78
-8.62%
-1.64
Investing Cash Flow
95.40
-34.10%
144.75
Cash Flow From Continuing Investing Activities
95.40
-34.10%
144.75
Net PPE Purchase And Sale
-0.36
+55.64%
-0.81
Purchase Of PPE
-0.36
+55.64%
-0.81
Capital Expenditure
-0.36
+55.64%
-0.81
Net Investment Purchase And Sale
95.76
-34.22%
145.56
Purchase Of Investment
-380.38
-25.16%
-303.92
Sale Of Investment
476.13
+5.93%
449.48
Financing Cash Flow
117.52
+234.94%
-87.09
Cash Flow From Continuing Financing Activities
117.52
+234.94%
-87.09
Net Common Stock Issuance
117.52
+234.94%
-87.09
Net Other Financing Charges
117.52
+234.94%
-87.09
Changes In Cash
87.11
+346.48%
-35.34
Beginning Cash Position
35.97
-49.56%
71.31
End Cash Position
123.08
+242.22%
35.97
Free Cash Flow
-126.16
-34.49%
-93.81
Amortization Of Securities
-10.31
+1.98%
-10.52
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category